Top searches

PL

Resources

B2RLaw advises Proteon Pharmaceuticals on a strategic partnership with Skretting

01/02/2021

B2RLaw has advised Proteon Pharmaceuticals on a strategic partnership with Skretting aimed at providing functional solutions to tackle health challenges in the aquaculture industry.

The companies will collaborate on developing products using bacteriophage technology to support aquaculture farmers as part of a holistic health strategy. The companies will work in a parallel R&D pipeline on the project.

The Partnership allows Proteon to grow its product portfolio in aquaculture and expand its presence worldwide. Both Proteon Pharmaceuticals and Skretting predict that the technology will become a valuable component of integrated management strategies on-farm with both feed and water applications under investigation.

Proteon Pharmaceuticals is a Polish originating biotech company with a vision to develop natural feed additives that help remove antibiotics from the food chain and improve animal and human health. The Company uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics.

Norwegian company, Skretting is the world’s largest producer of feeds for farmed fish. The Company has operations on five continents and produces 2.5 million tonnes of feed annually, for more than sixty species of fish. Skretting has 3,500 employees worldwide. Skretting has an R&D unit known as Skretting Aquaculture Research Centre (ARC) with the main objective to provide research and technical support regarding fish and shrimp feed. It has 140 employees representing 25 nationalities.

B2RLaw’s team advising Proteon Pharmaceuticals was led by Partner George Havaris and included Counsels Paulina Wyrostek and Malwina Niczke – Chmura.

George Havaris advises, “Proteon Pharmaceuticals is a Polish company that is well on the path to being a global leader in its field of operation. Animal health is a little-known industry in the wider public eye. However, animal health is fundamental to the health and well-being of humans. We congratulate Proteon and Skretting on this exciting Partnership and we look forward to continuing our support to Proteon on its growth path”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

13/11/2023

Danyila Zubach on WEB3: Impact The Economy Summit

WEB3: Impact the Economy was a discussion about the realities and opportunities of WEB3economy. It gathered policymakers, founders, CEOs of […]

MORE
24/10/2023

B2RLaw in the Bay Area and Silicon Valley on 24th October – 1st November

Here we go again on our US roadshow! Meet us in the Bay and Area Silicon Valley on 24th October […]

MORE
16/10/2023

B2RLaw advised Everfield UK Limited in the acquisition of 100% of the shares of a Polish start-up – Grafik Optymalny

Everfield is an international IT group that invests in companies with specialized software that solves operational problems for businesses. They […]

MORE
10/10/2023

B2RLaw advises Vestas on the acquisition of the ST3 Offshore for over PLN 170 million

B2RLaw advises Vestas on the acquisition of the ST3 Offshore for over PLN 170 million. Vestas, the Danish global giant […]

MORE
09/10/2023

B2RLaw’s team advised IQ Biozoom in connection with the investment support received from VC Link

B2RLaw’s team advised IQ Biozoom in connection with the investment support received from VC Link. IQ Biozoom is a Polish […]

MORE
22/09/2023

Julia Stroińska at the Modern Lawyer’s Conference “Law and Technology in the 21st Century”

Today at the Modern Lawyer’s Conference ”Law and Technology in the 21st Century“, organised by the Center for American Studies Poland, Julia Stroińska, Junior […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close